Evaluating the role of HER2-low versus HER2-0 status in predicting response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer

Alper Topal; Mustafa Başak

Makale detayları

Evaluating the role of HER2-low versus HER2-0 status in predicting response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer

Yazarlar:

Alper Topal | Mustafa Başak

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Chemotherapy

Dergi:

The European Research Journal Vol.11 Issue 5, pp.858-867

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001356989

pISSN:

2149-3189

Anahtar kelimeler:

Özet:

 Objectives: The classification of human epidermal growth factor receptor 2 HER2-low breast cancer has gained clinical relevance following the success of antibody-drug conjugates in this subgroup. However, its prognostic and predictive role, particularly in hormone receptor-positive HR early breast cancer treated with neoadjuvant chemotherapy NACT, remains unclear. This study aimed to evaluate the impact of HER2-low versus HER2-0 status on pathological complete response pCR and disease-free survival DFS in HR breast cancer patients undergoing NACT. Methods: A total of 216 HR and HER2-negative early breast cancer patients treated with NACT at Tokat Gaziosmanpasa University Hospital between January 2014 and January 2024 were retrospectively analyzed. HER2-low was defined as IHC 1 or 2 without gene amplification by FISH. pCR was assessed via the Miller-Payne grading system. Survival analyses were conducted using the Kaplan-Meier method; multivariate analyses were performed using Cox regression. Results: Of the 216 patients, 30 13.9 achieved pCR. There was no statistically significant difference in pCR P0.83 or DFS P0.12 between HER2-0 and HER2-low groups. However, patients with ER 10 had significantly higher pCR rates P0.005. Achieving pCR was associated with longer DFS P0.045. Conclusions: HER2-0 and HER2-low subgroups exhibited similar responses to NACT in HR breast cancer. Low ER expression was independently associated with higher pCR. Larger prospective studies are warranted to further define the biological and clinical implications of HER2 expression levels in early-stage HR breast cancer.

 Objectives: The classification of human epidermal growth factor receptor 2 HER2-low breast cancer has gained clinical relevance following the success of antibody-drug conjugates in this subgroup. However, its prognostic and predictive role, particularly in hormone receptor-positive HR early breast cancer treated with neoadjuvant chemotherapy NACT, remains unclear. This study aimed to evaluate the impact of HER2-low versus HER2-0 status on pathological complete response pCR and disease-free survival DFS in HR breast cancer patients undergoing NACT. Methods: A total of 216 HR and HER2-negative early breast cancer patients treated with NACT at Tokat Gaziosmanpasa University Hospital between January 2014 and January 2024 were retrospectively analyzed. HER2-low was defined as IHC 1 or 2 without gene amplification by FISH. pCR was assessed via the Miller-Payne grading system. Survival analyses were conducted using the Kaplan-Meier method; multivariate analyses were performed using Cox regression. Results: Of the 216 patients, 30 13.9 achieved pCR. There was no statistically significant difference in pCR P0.83 or DFS P0.12 between HER2-0 and HER2-low groups. However, patients with ER 10 had significantly higher pCR rates P0.005. Achieving pCR was associated with longer DFS P0.045. Conclusions: HER2-0 and HER2-low subgroups exhibited similar responses to NACT in HR breast cancer. Low ER expression was independently associated with higher pCR. Larger prospective studies are warranted to further define the biological and clinical implications of HER2 expression levels in early-stage HR breast cancer.

 Objectives: The classification of human epidermal growth factor receptor 2 HER2-low breast cancer has gained clinical relevance following the success of antibody-drug conjugates in this subgroup. However, its prognostic and predictive role, particularly in hormone receptor-positive HR early breast cancer treated with neoadjuvant chemotherapy NACT, remains unclear. This study aimed to evaluate the impact of HER2-low versus HER2-0 status on pathological complete response pCR and disease-free survival DFS in HR breast cancer patients undergoing NACT. Methods: A total of 216 HR and HER2-negative early breast cancer patients treated with NACT at Tokat Gaziosmanpasa University Hospital between January 2014 and January 2024 were retrospectively analyzed. HER2-low was defined as IHC 1 or 2 without gene amplification by FISH. pCR was assessed via the Miller-Payne grading system. Survival analyses were conducted using the Kaplan-Meier method; multivariate analyses were performed using Cox regression. Results: Of the 216 patients, 30 13.9 achieved pCR. There was no statistically significant difference in pCR P0.83 or DFS P0.12 between HER2-0 and HER2-low groups. However, patients with ER 10 had significantly higher pCR rates P0.005. Achieving pCR was associated with longer DFS P0.045. Conclusions: HER2-0 and HER2-low subgroups exhibited similar responses to NACT in HR breast cancer. Low ER expression was independently associated with higher pCR. Larger prospective studies are warranted to further define the biological and clinical implications of HER2 expression levels in early-stage HR breast cancer.

 Objectives: The classification of human epidermal growth factor receptor 2 HER2-low breast cancer has gained clinical relevance following the success of antibody-drug conjugates in this subgroup. However, its prognostic and predictive role, particularly in hormone receptor-positive HR early breast cancer treated with neoadjuvant chemotherapy NACT, remains unclear. This study aimed to evaluate the impact of HER2-low versus HER2-0 status on pathological complete response pCR and disease-free survival DFS in HR breast cancer patients undergoing NACT. Methods: A total of 216 HR and HER2-negative early breast cancer patients treated with NACT at Tokat Gaziosmanpasa University Hospital between January 2014 and January 2024 were retrospectively analyzed. HER2-low was defined as IHC 1 or 2 without gene amplification by FISH. pCR was assessed via the Miller-Payne grading system. Survival analyses were conducted using the Kaplan-Meier method; multivariate analyses were performed using Cox regression. Results: Of the 216 patients, 30 13.9 achieved pCR. There was no statistically significant difference in pCR P0.83 or DFS P0.12 between HER2-0 and HER2-low groups. However, patients with ER 10 had significantly higher pCR rates P0.005. Achieving pCR was associated with longer DFS P0.045. Conclusions: HER2-0 and HER2-low subgroups exhibited similar responses to NACT in HR breast cancer. Low ER expression was independently associated with higher pCR. Larger prospective studies are warranted to further define the biological and clinical implications of HER2 expression levels in early-stage HR breast cancer.

Makale detayları

Evaluating the role of HER2-low versus HER2-0 status in predicting response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer

Yazarlar:

Alper Topal | Mustafa Başak

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Chemotherapy

Dergi:

The European Research Journal Vol.11 Issue 5, pp.858-867

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001356989

pISSN:

2149-3189

Neoadjuvant chemotherapy

HER2-low

breast cancer

pathologic complete response

Sayı

Makale detayları

Evaluating the role of HER2-low versus HER2-0 status in predicting response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer

Yazarlar: Alper Topal | Mustafa Başak

Yayıncı: Prusa Medical Publishing

Ana Başlıklar: Chemotherapy

Dergi: The European Research Journal Vol.11 Issue 5, pp.858-867

Belge Tipi: Makale

Yayın Tarihi: 4/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001356989

pISSN: 2149-3189

Neoadjuvant chemotherapy

HER2-low

breast cancer

pathologic complete response

Sayı

Yazarlar:

Alper Topal | Mustafa Başak

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Chemotherapy

Dergi:

The European Research Journal Vol.11 Issue 5, pp.858-867

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001356989

pISSN:

2149-3189